Thank you to our members who cast their vote during the 2023 Annual General Meeting on November 14th, either in person or via proxy; your presence allowed us

HAE Canada, along with 12 other rare disease patient organizations, and Takeda Canada, unite to launch the I Am Number 12 campaign. This campaign elevates the voices of

Institut national d'excellence en santé et services sociaux (INESSS), whose missions is "to promote clinical excellence and the efficient use of resources in the health and social services

Qualifying HAE patients who access treatments through Veterans Affairs Canada (VAC) now have access to Takhzyro. Please speak to your treating HAE specialist about how you can access

Great news for eligible HAE patients in PEI. Lanadelumab (TAKHZYRO), a subcutaneous injection to routinely prevent attacks in patients with HAE Type I or II (12 years old

On March 22, 2023, the Canadian federal government announced their plan to provide up to $1.5 billion over three years to implement the Rare Disease Drug Strategy, as

We are thrilled to share that the Canadian Agency for Drugs and Technologies in Heath (CADTH) recently announced that they are recommending the oral treatment ORLADEYO (berotralstat), for

To honour Rare Disease Day 2023, HAE Canada President, and Ontario Regional Director, Michelle Cooper, spent the morning at a breakfast reception at Queen's Park in Toronto. Thank

For Canada's Rare Voices 2023, Patient Voice teamed up with 12 patients and their families, clinical experts and patient-centric biopharmas to shed some light on rare disease communities.

We have some announcements to make about the HAE Canada Board of Directors. The 2022-2023 Board of Directors was elected at our Annual General Meeting in November. Following